1. LIXTE expands clinical trial for LB-100 with MD Anderson and GSK. 2. Plans to double patient enrollment to 42 in ovarian cancer trial. 3. Initial findings expected in the first half of 2026. 4. LB-100 aims to enhance cancer treatment outcomes. 5. The company is pioneering a new cancer treatment field.
FAQ
Why Bullish?
The expansion of the clinical trial signifies growing confidence in LB-100's capabilities and potential market impact, which could drive LIXT's stock positively. Historical examples show similar gains for biotech firms post-positive trial announcements.
How important is it?
The article details critical advancements in LIXTE's research, which is pivotal for future stock performance. Positive advancements in clinical trials typically correlate with enhanced investor interest and stock valuation.
Why Long Term?
While initial findings won’t be available until 2026, the ongoing success and data collection could support LIXT's long-term growth and investor confidence, particularly if positive results emerge.
Related Companies
LIXTE Biotechnology Expands Clinical Trial for Ovarian Clear Cell Cancer
BOCA RATON, Fla., Dec. 23, 2025 (GLOBE NEWSWIRE) -- LIXTE Biotechnology Holdings, Inc. (“LIXTE” or the “Company”) (Nasdaq: LIXT) has announced a significant expansion of its clinical trial focusing on the treatment of ovarian clear cell cancer. This expansion includes a collaboration with The University of Texas MD Anderson Cancer Center and pharmaceutical manufacturer GSK, with plans to double the patient enrollment.
Trial Details and Patient Enrollment
The ongoing clinical trial, initiated in January 2024, investigates LIXTE's proprietary compound, LB-100, in combination with GSK’s Dostarlimab to improve immunotherapy effectiveness. The clinical trial is led by Dr. Amir Jazaeri, MD, a Professor of Gynecologic Oncology, at MD Anderson. A second trial site has been established at the Robert H. Lurie Comprehensive Cancer Center in conjunction with Northwestern University, led by Dr. Emily M. Hinchcliff, MD, MPH.
- The target number of patients in the trial will increase from 21 to 42.
- The initial target of 21 patients was successfully reached earlier this year.
- Initial data from the trial is expected to be presented in the first half of 2026.
Executive Insights on the Trial Expansion
Bas van der Baan, LIXTE’s Chief Scientific Officer, expressed confidence in the trial, stating, “We are gratified to be expanding the patient population of this important clinical trial. There is a tremendous unmet need in the treatment of ovarian clear cell cancer. Based on extensive published preclinical data, we believe LB-100 has the potential to significantly enhance chemotherapies and immunotherapies and improve patient outcomes.”
Geordan Pursglove, LIXTE’s Chief Executive Officer, added, “Expansion of this important trial is in keeping with LIXTE’s mission of treating cancer with exceptional, innovative therapies and cutting-edge technologies. With each step forward, we are hopeful of attaining our goal.”
About LIXTE Biotechnology Holdings, Inc.
LIXTE Biotechnology Holdings, Inc. is a clinical-stage pharmaceutical company dedicated to advancing cancer drug development. Its first-in-class lead clinical compound, LB-100, has shown promise in being well-tolerated by cancer patients and is associated with anti-cancer activity. LIXTE is focusing on enhancing chemotherapy and immunotherapy outcomes based on extensive preclinical data.
LIXTE’s innovative approach in the new field of cancer biology — known as activation lethality — signifies a paradigm shift in cancer treatment. The Company holds a comprehensive patent portfolio supporting its methodology. Ongoing proof-of-concept clinical trials are also in progress for Metastatic Colon Cancer beside Ovarian Clear Cell Carcinoma.
Forward-Looking Statements
In accordance with the Securities Act of 1933 and the Securities Exchange Act of 1934, this announcement includes forward-looking statements regarding LIXTE's financial position, business strategies, and anticipated outcomes from clinical trials. Terms such as “intend,” “believe,” “expect,” and similar phrases signal these forward-looking assertions. However, actual results may vary due to risks such as regulatory policies, competition, and financial resources.
Readers are encouraged to review the risk factors disclosed in LIXTE’s filings with the United States Securities and Exchange Commission at https://www.sec.gov.
Contact Information
For more information regarding LIXTE, please reach out via:
- Email: info@lixte.com
- General Phone: (631) 830-7092
- Investor Phone: (888) 289-5533
- Investor Relations: pwinvestor@pondel.com
- Roger Pondel: (310) 279-5965
- Laurie Berman: (310) 279-5962